Front. Oncol. Frontiers in Oncology Front. Oncol. 2234-943X Frontiers Media S.A. 10.3389/fonc.2025.1760931 Correction Correction: STRA6 polymorphisms are associated with EGFR mutations in locally-advanced and metastatic non-small cell lung cancer patients Muñiz-HernándezSaé 1 * Conceptualization Data curation Formal analysis Investigation Methodology Writing – original draft Velázquez-FernándezJesús Bernardino 2 Investigation Methodology Writing – review & editing Díaz-ChávezJosé 3 Methodology Writing – original draft Mondragón-FonsecaOmar 1 Methodology Writing – original draft Mayén-LoboYerye 1 4 Methodology Writing – original draft OrtegaAlberto 4 Methodology Writing – original draft López-LópezMarisol 4 Methodology Writing – original draft ArrietaOscar 1 5 * Conceptualization Funding acquisition Investigation Methodology Project administration Writing – original draft Writing – review & editing Laboratorio de Oncología Experimental, Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Ciudad de México, Mexico Unidad de Tecnología Ambiental, Centro de Investigación y Asistencia en Tecnología del Estado de Jalisco, Jalisco, Mexico Laboratorio de Carcinogénesis, Dirección de Investigación, Instituto Nacional de Cancerología, Ciudad de México, Mexico Laboratorio de Genética Molecular, Departamento de Sistemas Biológicos, Universidad Autónoma Metropolitana-Xochimilco, Ciudad de México, Mexico Unidad de Oncología Torácica, Instituto Nacional de Cancerología, Ciudad de México, Mexico Correspondence: Oscar Arrieta, ogar@unam.mx; Saé Muñiz-Hernández, sayide@hotmail.com 19 12 2025 2025 15 1760931 04 12 2025 05 12 2025 Copyright © 2025 Muñiz-Hernández, Velázquez-Fernández, Díaz-Chávez, Mondragón-Fonseca, Mayén-Lobo, Ortega, López-López and Arrieta. 2025 Muñiz-Hernández, Velázquez-Fernández, Díaz-Chávez, Mondragón-Fonseca, Mayén-Lobo, Ortega, López-López and Arrieta https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. A Correction on STRA6 polymorphisms are associated with EGFR mutations in locally-advanced and metastatic non-small cell lung cancer patients By Muñiz-Hernández S, Velázquez-Fernández JB, Díaz-Chávez J, Mondragón-Fonseca O, Mayén-Lobo Y, Ortega A, López-López M and Arrieta O (2020) Front. Oncol. 10:579561. doi: 10.3389/fonc.2020.579561 non-small cell lung cancer single nucleotide polymorphisms stimulated by retinoic acid 6 (STRA6) genotype retinol pathways section-at-acceptance Thoracic Oncology

In the published article, the legend of Figure 1 did not specify the meaning of the circles on the Kaplan–Meier curves.

The caption for Figure 1 has been updated to read:

“Kaplan–Meier curves for progression-free survival depending on rs974456 expression. Circles on the Kaplan–Meier curves represent censored observations.”

Kaplan–Meier curves for progression-free survival depending on rs974456 expression. Circles on the Kaplan–Meier curves represent censored observations.

Kaplan-Meier survival curve showing progression-free survival to chemotherapy for two groups: CC/CT (dotted line) with a median of 4.9 months, and TT (solid line) with a median of 3.3 months. A log-rank test yields a p-value of 0.044.

In the published article, the definition of progression-free survival (PFS) in the Statistical Analysis section was imprecise and could be interpreted as treating unacceptable toxicity and loss to follow-up as PFS events. In all survival analyses, however, PFS events consisted only of radiologic or clinical disease progression or death from any cause; patients who discontinued treatment due to unacceptable toxicity or were lost to follow-up were censored at the date of last disease assessment or last contact.

A correction has been made to the section Statistical Analysis, where the PFS definition previously read:

“PFS was defined as the time to an event from the date of initiating treatment until disease progression, unacceptable toxicity, death, or loss to follow-up.”

The corrected text now reads:

“Progression-free survival (PFS) was defined as the time from the date of initiating treatment to radiologic or clinical disease progression or death from any cause, whichever occurred first. Patients without progression or death, including those who discontinued treatment due to unacceptable toxicity or were lost to follow-up, were censored at the date of last disease assessment or last contact.”

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland